Study guide
4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport
Key Takeaways Explain This Topic AI
The kidneys receive 20–25% of resting cardiac output (1.0–1.2 L/min), with 90% perfusing the cortex for ultrafiltration while the vulnerable renal medulla receives only 10% to preserve the countercurrent osmotic gradient.
Glomerular filtration rate averages ~125 mL/min (~180 L/day) with a filtration fraction of ~0.20, driven by glomerular capillary hydrostatic pressure (~55–60 mmHg) opposing Bowman capsule hydrostatic (~15 mmHg) and capillary oncotic (~30 mmHg) pressures.
Renal autoregulation between MAP 80 and 180 mmHg is mediated by the myogenic response and tubuloglomerular feedback, in which macula densa cells sense luminal NaCl and release ATP/adenosine to modulate afferent arteriolar tone.
Angiotensin II preferentially constricts the efferent arteriole to preserve glomerular capillary pressure and GFR during hypoperfusion; blocking this mechanism with ACE inhibitors or ARBs precipitates acute renal failure in hypovolemic patients.
The thick ascending limb of the loop of Henle actively transports solutes via the furosemide-sensitive NKCC2 cotransporter without water permeability, establishing the hypertonic medullary gradient that enables ADH-mediated water conservation via aquaporin-2.
Last updated: October 2026
4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport
Renal physiology is a core domain in perioperative medicine and critical care. The kidneys are responsible for clearing metabolic waste, regulating extracellular fluid volume and osmolarity, maintaining acid-base and electrolyte equilibrium, and producing endocrine mediators such as renin, erythropoietin, and calcitriol.
- 1. Renal Hemodynamics and Regional Perfusion
- Renal Blood Flow (RBF) and Renal Plasma Flow (RPF)
The paired kidneys weigh approximately 300 g (0.5% of total body weight) yet receive 1.0 to 1.2 L/min of blood , representing 20% to 25% of resting cardiac output . This enormous blood flow is not driven by parenchymal metabolic demand, but is required to sustain high rates of glomerular ultrafiltration .
With a normal hematocrit ( H c t Hct Hc t ) of 0.40 to 0.45, Renal Plasma Flow (RPF) is calculated as:
R P F = R B F × ( 1 − H c t ) ≈ 1200 × ( 1 − 0.45 ) ≈ 600 to 660 mL/min RPF = RBF \times (1 - Hct) \approx 1200 \times (1 - 0.45) \approx 600\text{ to } 660\text{ mL/min} RPF = RBF × ( 1 − Hc t ) ≈ 1200 × ( 1 − 0.45 ) ≈ 600 to 660 mL/min
Cortical vs Medullary Perfusion: The Ischemic Vulnerability of the Medulla
Renal blood flow is distributed unevenly between anatomical zones:
Renal Cortex (~90% of RBF): High blood flow rate (~5 mL/g/min). Oxygen extraction is low (~10–15%), giving renal venous blood a bright red appearance ( S v O 2 ≈ 85 – 90 % S_v\text{O}_2 \approx 85\text{--}90\% S v O 2 ≈ 85 – 90% ). The cortex contains all glomeruli and proximal tubules and is specialized for filtration and bulk reabsorption.
Renal Medulla (~10% of RBF): Perfused solely by the specialized, elongated capillary loops of the vasa recta branching from juxtamedullary efferent arterioles. Blood flow is low (~0.5–1 mL/g/min). This sluggish blood flow is a vital physiological adaptation: high blood flow would rapidly wash out the hyperosmolar sodium and urea gradient established by the loop of Henle, eliminating the kidney's ability to concentrate urine.
Clinical Trap: Because oxygen delivery to the medulla is low and the thick ascending limb has high metabolic demands driven by active Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase transport, tissue P O 2 P\text{O}_2 P O 2 in the deep medulla is only 10 to 20 mmHg . Consequently, the medullary thick ascending limb and the S3 straight segment of the proximal tubule are exquisitely vulnerable to ischemic acute tubular necrosis (ATN) during perioperative hypotension, hypovolemia, or aortic cross-clamping.
- 2. Glomerular Ultrafiltration and Starling Forces
- Glomerular Filtration Rate (GFR) and Filtration Fraction (FF)
Normal GFR: Approximately 120 to 125 mL/min in healthy adults (~180 L of ultrafiltrate per day).
Filtration Fraction (FF): The fraction of renal plasma flow that filters across the glomerular basement membrane into Bowman's space:
F F = G F R R P F = 125 mL/min 600 mL/min ≈ 0.20 ( 20 % ) FF = \frac{GFR}{RPF} = \frac{125\text{ mL/min}}{600\text{ mL/min}} \approx 0.20\quad (20\%) FF = RPF GFR = 600 mL/min 125 mL/min ≈ 0.20 ( 20% )
Transcapillary Starling Forces
Glomerular filtration obeys the Starling principle across the filtration barrier:
P net = ( P gc − P bs ) − ( π gc − π bs ) P_{\text{net}} = (P_{\text{gc}} - P_{\text{bs}}) - (\pi_{\text{gc}} - \pi_{\text{bs}}) P net = ( P gc − P bs ) − ( π gc − π bs )
Force Value at Afferent End Value at Efferent End Physiological Description
P gc P_{\text{gc}} P gc (Capillary Hydrostatic) ~55–60 mmHg ~53–58 mmHg Unusually high; held constant by resistance of downstream efferent arteriole; favors filtration
P bs P_{\text{bs}} P bs (Bowman Space Hydrostatic) ~15 mmHg ~15 mmHg Fluid backpressure within the nephron lumen; opposes filtration; elevated in urinary tract obstruction
π gc \pi_{\text{gc}} π gc (Capillary Oncotic) ~25–28 mmHg ~32–35 mmHg Plasma proteins do not filter; oncotic pressure rises along capillary length as water exits; opposes filtration
π bs \pi_{\text{bs}} π bs (Bowman Space Oncotic) ~0 mmHg ~0 mmHg Ultrafiltrate is virtually protein-free under normal barrier integrity; favors filtration
P net P_{\text{net}} P net (Net Filtration Pressure) +12 to +15 mmHg 0 to +5 mmHg Positive net vector drives continuous filtration along capillary; approaches filtration equilibrium
The Glomerular Filtration Barrier
The filtration barrier consists of three layers with size- and charge-selective properties:
Fenestrated endothelial cells: Fenestrae measure 70–100 nm, retaining cellular blood elements while allowing passage of all plasma solutes.
Glomerular basement membrane (GBM): Meshwork of type IV collagen, laminin, and negatively charged heparan sulfate proteoglycans. Provides mechanical strength and repels polyanionic proteins.
Podocyte foot processes (visceral epithelial layer): Interdigitate to create slit pores bridged by slit diaphragms containing nephrin and podocin (pore size ~4–14 nm).
Permeability criteria: Solutes with molecular radius < 2 nm < 2\text{ nm} < 2 nm (e.g., water, glucose, electrolytes, inulin) filter freely. Solutes > 4.2 nm > 4.2\text{ nm} > 4.2 nm are completely excluded. For molecules in the intermediate range (e.g., albumin, radius ~3.6 nm, molecular weight 69 kDa), the negative charge of the barrier provides electrostatic repulsion. In nephrotic diseases, loss of these negative charges causes marked albuminuria despite preserved pore sizes.
3. Autoregulation and Hormonal Control of Glomerular Hemodynamics
Both RBF and GFR remain relatively constant across a mean arterial pressure range of 80 to 180 mmHg .
Autoregulatory Mechanisms
Myogenic Mechanism: An intrinsic property of vascular smooth muscle in the afferent arteriole . When perfusion pressure rises, wall stretch opens stretch-activated cation channels, causing membrane depolarization, calcium entry through voltage-gated L-type channels, and arteriolar constriction, preventing excessive transmission of pressure to glomerular capillaries.
Tubuloglomerular Feedback (TGF): Mediated by the juxtaglomerular apparatus (JGA) :
If GFR rises, fluid flow through the loop of Henle accelerates, exceeding the reabsorptive capacity of the loop.
Increased amounts of Na + \text{Na}^+ Na + and Cl − \text{Cl}^- Cl − reach the macula densa cells located in the early distal tubule.
Macula densa cells take up NaCl via luminal NKCC2 cotransporters . Intracellular sodium and chloride accumulate, causing cellular swelling and ATP release into the interstitial space.
Extracellular nucleotidases convert ATP to adenosine , which binds to A 1 A_1 A 1 adenosine receptors on adjacent extraglomerular mesangial cells and afferent arteriolar vascular smooth muscle.
Intracellular calcium rises, triggering selective afferent arteriolar vasoconstriction , reducing P gc P_{\text{gc}} P gc and restoring GFR to baseline. Tubuloglomerular Feedback Loop:
- Increased GFR
- |
- v
- Increased NaCl delivery to Macula Densa (via NKCC2)
- |
- v
- Release of ATP and Adenosine into JGA interstitium
- |
- v
- Activation of A1 Adenosine Receptors on Afferent Arteriole
- |
- v
- Afferent Arteriolar Vasoconstriction ---> Normalizes GFR
- Renin-Angiotensin-Aldosterone System (RAAS) and Efferent Tone
Renin release: Synthesized and stored in juxtaglomerular granular cells of the afferent arteriole. Secretion is triggered by: (1) decreased stretch in afferent arteriolar baroreceptors; (2) renal sympathetic nerve stimulation (via β 1 \beta_1 β 1 -adrenergic receptors); and (3) decreased NaCl delivery sensed by the macula densa.
Angiotensin II action: Angiotensin II has a vastly higher density of A T 1 AT_1 A T 1 receptors on the efferent arteriole than on the afferent arteriole. At low to physiological concentrations, Angiotensin II selectively constricts the efferent arteriole :
Efferent constriction increases downstream resistance, which elevates glomerular capillary hydrostatic pressure ( P gc P_{\text{gc}} P gc ), maintaining GFR even during systemic hypoperfusion or moderate hypovolemia.
Prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 , PG I 2 ): Synthesized in response to sympathetic activation and Angiotensin II to dilate the afferent arteriole , shielding the glomerulus from excessive vasoconstrictive ischemia.
Perioperative Clinical Trap: The "Triple Whammy"
Under general anaesthesia, systemic vascular resistance falls. If a patient is taking an ACE inhibitor (or ARB) , compensatory efferent arteriolar constriction is blocked. If the patient also takes an NSAID , renal prostaglandin synthesis is blocked, preventing compensatory afferent arteriolar vasodilation. When combined with hypovolemia or perioperative hypotension, the afferent arteriole remains constricted while the efferent arteriole dilates freely; P gc P_{\text{gc}} P gc crashes, and GFR plummets, precipitating acute kidney injury (AKI).
4. Tubular Transport Mechanisms Along the Nephron
Nephron Segment % Filtered Na Reabsorbed Major Transporters & Channels Water Permeability Pharmacological Targets & Hormones
Proximal Tubule (PCT) 65–70% Apical NHE3 ( Na + / H + \text{Na}^+/H^+ Na + / H + ), SGLT2 ( Na + \text{Na}^+ Na + -glucose); Basolateral Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase, NBCe1 ( Na + − 3 HCO 3 − \text{Na}^+-3\text{HCO}_3^- Na + − 3 HCO 3 − ) Extremely high (Aquaporin-1); isotonic reabsorption Acetazolamide (carbonic anhydrase inhibitor); SGLT2 inhibitors (dapagliflozin)
Thin Descending Limb 0% No active solute transport High (Aquaporin-1) Fluid becomes hypertonic (concentrating segment)
Thick Ascending Limb (TAL) 20–25% Apical NKCC2 ( Na + − K + − 2 Cl − \text{Na}^+-\text{K}^+-2\text{Cl}^- Na + − K + − 2 Cl − ), ROMK ( K + K^+ K + recycling); Basolateral ClC-Kb, Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase Impermeable to water Loop diuretics (furosemide, bumetanide) ; creates hypertonic medullary interstitium
Distal Convoluted Tubule 5–8% Apical NCCT ( Na + − Cl − \text{Na}^+-\text{Cl}^- Na + − Cl − ); Apical TRPV5 ( Ca 2 + \text{Ca}^{2+} Ca 2 + channel) Impermeable to water (cortical diluting segment) Thiazide diuretics (hydrochlorothiazide); Parathyroid hormone (PTH stimulates Ca 2 + \text{Ca}^{2+} Ca 2 + reabsorption)
Collecting Duct (Principal Cells) 2–5% Apical ENaC (epithelial Na + \text{Na}^+ Na + channel), ROMK ( K + K^+ K + secretion); Basolateral Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase Variable; regulated by Vasopressin/ADH via Aquaporin-2 Aldosterone (stimulates ENaC/ATPase); Spironolactone/eplerenone (MRAs); Amiloride (ENaC blocker)
Collecting Duct (Intercalated Cells) 0% Type A: Apical H + H^+ H + -ATPase, H + / K + H^+/\text{K}^+ H + / K + -ATPase; Basolateral AE1 ( Cl − / HCO 3 − \text{Cl}^-/\text{HCO}_3^- Cl − / HCO 3 − ). Type B: Apical pendrin Impermeable to water Regulates acid-base homeostasis; Type A secretes H + H^+ H + and reabsorbs HCO 3 − \text{HCO}_3^- HCO 3 − ; Type B secretes HCO 3 − \text{HCO}_3^- HCO 3 −
Proximal Convoluted Tubule (PCT)
Reabsorbs the bulk of ultrafiltrate isotonically. Reabsorbs 100% of filtered glucose and amino acids , 65–70% of Na + , Cl − , K + \text{Na}^+, \text{Cl}^-, \text{K}^+ Na + , Cl − , K + , and water , and 85–90% of filtered bicarbonate :
Bicarbonate Reabsorption: Filtered HCO 3 − \text{HCO}_3^- HCO 3 − cannot cross the apical membrane directly. Apical NHE3 secretes H + H^+ H + into the lumen in exchange for Na + \text{Na}^+ Na + . In the tubular lumen, brush-border carbonic anhydrase type IV (CA-IV) dehydrates H + + HCO 3 − → H 2 O + C O 2 H^+ + \text{HCO}_3^- \rightarrow H_2O + CO_2 H + + HCO 3 − → H 2 O + C O 2 . Molecular C O 2 CO_2 C O 2 diffuses into the proximal tubule cell, where intracellular carbonic anhydrase type II (CA-II) rehydrates it: C O 2 + H 2 O → H + + HCO 3 − CO_2 + H_2O \rightarrow H^+ + \text{HCO}_3^- C O 2 + H 2 O → H + + HCO 3 − . The intracellular H + H^+ H + is recycled back via NHE3, while HCO 3 − \text{HCO}_3^- HCO 3 − exits the basolateral membrane via the Na + − 3 HCO 3 − \text{Na}^+-3\text{HCO}_3^- Na + − 3 HCO 3 − cotransporter (NBCe1).
Glucose Transport: Mediated by SGLT2 (high capacity, low affinity in early S1/S2 segments) and SGLT1 (in S3). Transport maximum ( T m T_m T m ) for glucose is approximately 375 mg/min (corresponding to an arterial plasma glucose concentration of ~10 to 11 mmol/L or 180–200 mg/dL). Above this threshold, glucose appears in the urine, causing osmotic diuresis.
Loop of Henle and Countercurrent Multiplication
The countercurrent multiplier establishes an osmotic gradient extending from 300 mOsm/kg in the renal cortex to 1200 mOsm/kg at the papillary tip :
Thin descending limb: Highly permeable to water via aquaporin-1, but impermeable to sodium and urea. As fluid descends into the hyperosmolar medulla, water leaves down the osmotic gradient into the interstitium, concentrating luminal fluid to 1200 mOsm/kg.
Thick ascending limb (TAL): Impermeable to water. Actively pumps Na + , K + , \text{Na}^+, \text{K}^+, Na + , K + , and 2 Cl − 2\text{Cl}^- 2 Cl − out of the lumen into the interstitium via NKCC2 . Potassium ions leak back into the tubular lumen via apical ROMK channels. This outward positive potassium flux generates a lumen-positive transepithelial potential (+8 to +10 mV) , which drives the paracellular reabsorption of cations: magnesium ( Mg 2 + \text{Mg}^{2+} Mg 2 + , 60% of total filtered load) and calcium ( Ca 2 + \text{Ca}^{2+} Ca 2 + , 20% of filtered load) .
Loop Diuretics (furosemide): Compete for the chloride-binding site on NKCC2, abolishing active ion reabsorption, dissipating the medullary concentration gradient, and extinguishing the lumen-positive potential, which leads to marked urinary wasting of Na + , Cl − , K + , Ca 2 + \text{Na}^+, \text{Cl}^-, \text{K}^+, \text{Ca}^{2+} Na + , Cl − , K + , Ca 2 + , and Mg 2 + \text{Mg}^{2+} Mg 2 + .
Collecting Duct and Vasopressin (ADH)
Fine-tuning of water excretion occurs in the cortical and medullary collecting ducts:
Arginine Vasopressin (ADH): Synthesized in the hypothalamus and released from the posterior pituitary in response to hyperosmolality (osmoreceptors in the anterior hypothalamus sensitive to a 1% shift) or hypovolemia (carotid/aortic baroreceptors sensitive to a 5–10% drop in volume).
Molecular cascade: ADH binds basolateral V 2 V_2 V 2 receptors → G s \rightarrow G_s → G s protein activation → \rightarrow → adenylyl cyclase stimulation → \rightarrow → intracellular cAMP rises → \rightarrow → Protein Kinase A phosphorylates aquaporin-2 (AQP2) storage vesicles → \rightarrow → rapid exocytic insertion of AQP2 tetramers into the apical (luminal) membrane .
Water moves passively out of the lumen through AQP2, and exits across the basolateral membrane via constitutively expressed aquaporin-3 and aquaporin-4 into the hypertonic medullary interstitium, concentrating urine up to 1200 mOsm/kg. In the absence of ADH (diabetes insipidus), apical membranes remain impermeable to water, producing large volumes of dilute urine (~50 mOsm/kg).
- 5. Renal Clearance Concepts and Diagnostic Markers
- Renal Clearance Equation
Clearance ( C x C_x C x ) is defined as the volume of plasma completely cleared of a substance by the kidneys per unit time:
C x = U x × V P x C_x = \frac{U_x \times V}{P_x} C x = P x U x × V
Where U x U_x U x is urine concentration of x x x , V V V is urine flow rate (mL/min), and P x P_x P x is arterial plasma concentration of x x x .
Inulin Clearance: Inulin is an exogenous fructose polymer that is freely filtered at the glomerulus and is neither reabsorbed, secreted, synthesized, nor metabolized by renal tubules. Therefore, inulin clearance is the experimental gold standard for measuring GFR ( C inulin = G F R C_{\text{inulin}} = GFR C inulin = GFR ).
Creatinine Clearance: Creatinine is an endogenous breakdown product of muscle creatine phosphate. It is freely filtered at the glomerulus, but approximately 10% to 15% is actively secreted by proximal tubular organic cation transporters. Consequently, creatinine clearance slightly overestimates true GFR . However, common clinical colorimetric assays (Jaffé reaction) also overestimate serum creatinine due to non-creatinine chromogens; fortuitously, these two errors partially offset one another.
Serum Creatinine Non-Linearity: Serum creatinine has an inverse hyperbolic relationship with GFR. Because the curve is flat at high GFRs, a patient can lose up to 50% of functional nephrons before serum creatinine rises above the upper limit of the normal reference range.
Para-Aminohippuric Acid (PAH) Clearance: PAH is freely filtered and avidly secreted by proximal tubule cells via organic anion transporters, achieving an extraction ratio of ~90% on a single pass. At low plasma concentrations, PAH clearance measures Effective Renal Plasma Flow (ERPF ~600 mL/min) . True R P F = C PAH 0.90 ≈ 660 mL/min RPF = \frac{C_{\text{PAH}}}{0.90} \approx 660\text{ mL/min} RPF = 0.90 C PAH ≈ 660 mL/min .